Payment overview · 2025
General Payments
$1,556.93
81 reported records · 15 companies
Healthcare provider profile · identity verified
Inna Kigel, DO
Allopathic & Osteopathic Physicians|Family Medicine · KEW GARDENS, NY · NPI 1235210956
Verified facts
What the public records show
CMS Open Payments records show Inna Kigel, DO received $1,556.93 in general payments during 2025 across 81 reported records.
GlaxoSmithKline, LLC. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Linzess, Ozempic, Trelegy Ellipta, Trintellix, Xifaxan, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 457 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Viberzi by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $249.81 | 16.1% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $233.29 | 15.0% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $226.64 | 14.6% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $197.67 | 12.7% | 9 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $194.86 | 12.5% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $126.14 | 8.1% | 5 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $81.07 | 5.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $47.60 | 3.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.53 | 2.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $41.02 | 2.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $39.82 | 2.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.17 | 1.5% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.40 | 1.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.54 | 1.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.37 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,556.93 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $249.81 | 18 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $216.67 | 10 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $194.86 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $148.55 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $138.12 | 8 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $137.12 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $126.39 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $110.44 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $103.58 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $103.58 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.75 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $47.60 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $41.65 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $39.82 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 219 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 124 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 191 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 457 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 160 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 181 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 53 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
219 | 68 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
457 | 60 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
185 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
124 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
191 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
181 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
191 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 25 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Linzess | Linaclotide | 457 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 379 | 74 |
| Azithromycin | Azithromycin | 333 | 175 |
| Diclofenac Sodium | Diclofenac Sodium | 329 | 68 |
| Vascepa | Icosapent Ethyl | 275 | 53 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 272 | 36 |
| Zenpep | Lipase/Protease/Amylase | 269 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 267 | 54 |
| Clonidine Hcl | Clonidine Hcl | 263 | 76 |
| Fluticasone Propionate | Fluticasone Propionate | 259 | 80 |
| Myrbetriq | Mirabegron | 237 | 39 |
| Creon | Lipase/Protease/Amylase | 219 | 68 |
| Losartan Potassium | Losartan Potassium | 203 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 195 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 39 |
| Jardiance | Empagliflozin | 191 | 28 |
| Dexilant | Dexlansoprazole | 190 | 31 |
| Synthroid | Levothyroxine Sodium | 185 | 26 |
| Gabapentin | Gabapentin | 184 | 54 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 181 | 54 |
| Montelukast Sodium | Montelukast Sodium | 177 | 38 |
| Eliquis | Apixaban | 171 | 24 |
| Dexlansoprazole Dr | Dexlansoprazole | 166 | 41 |
| Ozempic | Semaglutide | 160 | 25 |
| Metformin Hcl | Metformin Hcl | 146 | 38 |
| Lorazepam | Lorazepam | 143 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 28 |
| Januvia | Sitagliptin Phosphate | 141 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 132 | 30 |
| Meclizine Hcl | Meclizine Hcl | 132 | 38 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 126 | 43 |
| Farxiga | Dapagliflozin Propanediol | 124 | 19 |
| Crestor | Rosuvastatin Calcium | 123 | 19 |
| Levofloxacin | Levofloxacin | 122 | 88 |
| Carvedilol | Carvedilol | 115 | 25 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 115 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 111 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 19 |
| Enalapril Maleate | Enalapril Maleate | 109 | 25 |
| Edarbi | Azilsartan Medoxomil | 108 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 30 |
| Omeprazole | Omeprazole | 102 | 34 |
| Xarelto | Rivaroxaban | 100 | 11 |
| Lisinopril | Lisinopril | 98 | 16 |
| Furosemide | Furosemide | 95 | 19 |
| Lidocaine | Lidocaine | 94 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 89 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 87 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 24 |
| Allopurinol | Allopurinol | 84 | 28 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 82 | 21 |
| Spironolactone | Spironolactone | 82 | 17 |
| Ranolazine Er | Ranolazine | 81 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 21 |
| Ursodiol | Ursodiol | 78 | 17 |
| Memantine Hcl | Memantine Hcl | 74 | 19 |
| Glimepiride | Glimepiride | 73 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 73 | 13 |
| Labetalol Hcl | Labetalol Hcl | 72 | 22 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 69 | 15 |
| Ezetimibe | Ezetimibe | 67 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 50 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 65 | 18 |
| Famotidine | Famotidine | 65 | 16 |
| Alcohol Pads | Alcohol Antiseptic Pads | 64 | 18 |
| Ibuprofen | Ibuprofen | 64 | 34 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 64 | 53 |
| Azelastine Hcl | Azelastine Hcl | 63 | 28 |
| Meloxicam | Meloxicam | 62 | 19 |
| Doxepin Hcl | Doxepin Hcl | 61 | 26 |
| Livalo | Pitavastatin Calcium | 61 | suppressed |
| Potassium Chloride | Potassium Chloride | 59 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 57 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | suppressed |
| Repaglinide | Repaglinide | 57 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 57 | suppressed |
| Irbesartan | Irbesartan | 56 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 11 |
| Donepezil Hcl | Donepezil Hcl | 54 | 13 |
| Glipizide | Glipizide | 54 | 11 |
| Simvastatin | Simvastatin | 54 | 11 |
| Nystatin | Nystatin | 53 | 21 |
| Trintellix | Vortioxetine Hydrobromide | 53 | 11 |
| Tramadol Hcl | Tramadol Hcl | 52 | 24 |
| Atenolol | Atenolol | 51 | 12 |
| Fluconazole | Fluconazole | 51 | 25 |
| Propranolol Hcl | Propranolol Hcl | 51 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | suppressed |
| Alprazolam | Alprazolam | 48 | 13 |
| Celecoxib | Celecoxib | 48 | 12 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 48 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 48 | 13 |
| Finasteride | Finasteride | 47 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 46 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 45 | suppressed |
| Procto-Med Hc | Hydrocortisone | 44 | 14 |
| Hydrocortisone | Hydrocortisone | 41 | 18 |
| Valsartan | Valsartan | 41 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Lactulose | Lactulose | 39 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 38 | 13 |
| Methylprednisolone | Methylprednisolone | 38 | 30 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Mupirocin | Mupirocin | 37 | 21 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 36 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 36 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | 13 |
| Halobetasol Propionate | Halobetasol Propionate | 34 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 34 | 23 |
| Naproxen | Naproxen | 33 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 32 | 13 |
| Ztlido | Lidocaine | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | 14 |
| Diovan | Valsartan | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Clotrimazole | Clotrimazole | 30 | 11 |
| Diazepam | Diazepam | 30 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 12 |
| Proctozone-Hc | Hydrocortisone | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Loperamide | Loperamide Hcl | 29 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 18 |
| Diclofenac Epolamine | Diclofenac Epolamine | 28 | suppressed |
| Trulance | Plecanatide | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Felodipine Er | Felodipine | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Nexium | Esomeprazole Magnesium | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 11 |
| Valacyclovir | Valacyclovir Hcl | 26 | 15 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Xifaxan | Rifaximin | 25 | suppressed |
| Bystolic | Nebivolol Hcl | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 16 |
| Erythromycin | Erythromycin Base | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Fioricet | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Glyburide | Glyburide | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Benicar | Olmesartan Medoxomil | 20 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Ibsrela | Tenapanor Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 13 |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ambien | Zolpidem Tartrate | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Norvasc | Amlodipine Besylate | 18 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Prolia | Denosumab | 18 | 12 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Pennsaid | Diclofenac Sodium | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Viberzi | Eluxadoline | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Gralise | Gabapentin | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Celebrex | Celecoxib | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Plavix | Clopidogrel Bisulfate | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Toprol Xl | Metoprolol Succinate | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,556.93 · 81 records | GlaxoSmithKline, LLC. | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CREON, Cologuard Collection Kit, ELYXYB - CELECOXIB, FARXIGA, GEMTESA, IQIRVO, JARDIANCE, LINZESS, MOUNJARO, Ohtuvayre, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, Wegovy, XIFAXAN, ZEPBOUND, ZTLido | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error